0
0
Read Time:3 Minute, 31 Second
The IVD Reagents Market is projected to experience a compound annual growth rate (CAGR) of 5.3% during the forecast period, reaching a market value of $79.76 billion by 2031, according to Meticulous Research®. IVD reagents, including oligonucleotides, antibodies, nucleic acid probes, purified proteins or peptides, and other crucial materials, play a significant role in disease diagnosis, prevention, and the manufacturing of diagnostic kits and assays. Their applications extend across research and diagnostic sectors, fueling ongoing developments in healthcare.
Market Drivers and Opportunities:
The market’s growth is primarily driven by the increasing prevalence of infectious diseases, rising investments in research, adoption of advanced diagnostic technologies, and expanding research in proteomics and genomics. Additionally, the expansion of clinical laboratories and a growing focus on personalized medicine and protein therapeutics in emerging economies present further growth opportunities.
Challenges:
The market faces challenges, including stringent regulations surrounding antigen-specific reagents and the high costs associated with these reagents. Furthermore, limited reimbursement policies in some regions create obstacles to broader market expansion.
Leading Companies in the IVD Reagents Market:
Thermo Fisher Scientific Inc. (U.S.)
Established in 1956 and headquartered in Massachusetts, Thermo Fisher operates across four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services. Its Clinical Diagnostics business within the Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagents for various sectors, including healthcare and pharmaceuticals. Thermo Fisher’s IVD reagents reach a global market through subsidiaries and facilities across multiple continents.
Becton, Dickinson and Company (BD) (U.S.)
Founded in 1897 in New Jersey, BD is a global leader in medical technology. Through its BD Life Sciences segment, BD offers IVD reagents within its Biosciences category, serving hospitals, laboratories, and research institutions worldwide. With operations across the U.S., Europe, and Asia, BD provides innovative diagnostic solutions backed by extensive R&D facilities in multiple countries.
Merck KGaA (Germany)
Operating since 1668 and headquartered in Darmstadt, Merck KGaA delivers health and science solutions through its Life Science segment, which supports the IVD reagents market. Its expansive product range and global manufacturing sites make it a prominent supplier across Europe, North America, and Asia-Pacific.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5110
Bio-Rad Laboratories, Inc. (U.S.)
Headquartered in California and founded in 1952, Bio-Rad produces diagnostic and life science research tools, offering over 3,000 clinical diagnostics products, including IVD reagents. Bio-Rad serves healthcare facilities and laboratories worldwide, with a strong distribution network in the U.S., Europe, and Asia.
Agilent Technologies, Inc. (U.S.)
Established in 1999, Agilent specializes in solutions for life sciences and diagnostics, operating through its Diagnostics & Genomics segment. The company’s Dako brand provides diagnostic antibodies and reagents globally, supported by research and manufacturing centers across the U.S., Europe, and Asia-Pacific.
Abcam plc (U.K.)
Since 1998, Abcam has developed research-grade antibodies and proteins for IVD applications, using proprietary RabMAb technology to produce high-quality monoclonal antibodies. Abcam’s extensive network spans Europe, the U.S., and Asia, catering to both academic and clinical research markets.
Hologic Inc. (U.S.)
Hologic, founded in 1985, is a Massachusetts-based medical technology company, offering IVD reagents through its Diagnostics segment. It provides diagnostic solutions directly and through partners, with a presence in North America, Europe, and Asia.
QIAGEN N.V. (Netherlands)
Established in 1984, QIAGEN is a global provider of molecular diagnostics and life science solutions, offering IVD reagents for oncology and infectious disease diagnostics. With subsidiaries in over 25 countries, QIAGEN maintains a strong global reach through partnerships and direct sales.
Buy Now: https://www.meticulousresearch.com/Checkout/21348226
Each of these companies contributes to the dynamic landscape of the IVD reagents market, leveraging global networks, robust R&D, and a focus on innovation to meet the evolving demands of healthcare diagnostics.
Contact Us:
Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
